期刊
CELL CYCLE
卷 16, 期 16, 页码 1489-1498出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/15384101.2017.1339849
关键词
MYC; MYCL; MYCN; small cell lung cancer; SCLC; GEMM; mouse models
类别
资金
- German Ministry of Science and Education (BMBF) as part of the e:Med program (MILES) [01ZX1406]
- V Scholar award from The V Foundation for Cancer Research
- American Cancer Society [RSG-13-300-01-TBG]
- NIH [R01CA187457]
- Damon Runyon Cancer Research Foundation [DRR-26-13]
Small cell lung cancer (SCLC) is one of the most deadly cancers and currently lacks effective targeted treatment options. Recent advances in the molecular characterization of SCLC has provided novel insight into the biology of this disease and raises hope for a paradigm shift in the treatment of SCLC. We and others have identified activation of MYC as a driver of susceptibility to Aurora kinase inhibition in SCLC cells and tumors that translates into a therapeutic option for the targeted treatment of MYC-driven SCLC. While MYC shares major features with its paralogs MYCN and MYCL, the sensitivity to Aurora kinase inhibitors is unique for MYC-driven SCLC. In this review, we will compare the distinct molecular features of the 3 MYC family members and address the potential implications for targeted therapy of SCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据